[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.168.21. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 27, 1995

Clozapine Treatment of Schizophrenia

Author Affiliations

From the Experimental Therapeutics Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Md.

JAMA. 1995;274(12):981-983. doi:10.1001/jama.1995.03530120073044
Abstract

SELECTED CASE  A 27-year-old woman was admitted to the National Institutes of Health Clinical Center, Bethesda, Md, for inpatient research protocol for schizophrenia. She first experienced behavioral disturbances at 13 years of age when she became withdrawn and isolated from friends and family. She reported auditory hallucinations for the first time at 16 years and developed delusions of control and persecution over ensuing months. Suicidal ruminations culminated in a serious suicide attempt and her first hospitalization at the age of 17 years. Although standard antipsychotic drugs reduced her delusions, the patient remained socially isolated and had symptom exacerbation when under stress. She discontinued antipsychotic drug treatment because of adverse effects on several occasions; in each case, she became acutely psychotic. Prior to her admission to the National Institute of Mental Health, she was hospitalized 15 times, including several hospitalizations mandated by the court because of risk to herself and to

First Page Preview View Large
First page PDF preview
First page PDF preview
×